A Open-label, Single-arm Clinical Trial Designed to Evaluate the Safety, Pharmacokinetic , and Efficacy of the GK01 Cell Injection in Combination With a PD-1 Monoclonal Antibody for the Treatment of Advanced Solid Tumors.
Latest Information Update: 18 Feb 2026
At a glance
- Drugs GK 01 Beijing Geekgene Technology (Primary)
- Indications Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Acronyms GK01IIT-TZ03
- Sponsors Beijing Geekgene Technology
Most Recent Events
- 18 Feb 2026 New trial record